ONCORUS INC (ONCR) Stock Price, Forecast & Analysis
USA - NASDAQ:ONCR - US68236R1032 - Common Stock
ONCR Key Statistics, Chart & Performance
The current stock price of ONCR is 0.1206 USD. In the past month the price decreased by -60.83%. In the past year, price decreased by -91.45%.
ONCR Latest News, Press Relases and Analysis
ONCR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.85 | 381.52B | ||
| AMGN | AMGEN INC | 13.57 | 159.37B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.28 | 108.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.97 | 66.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 829.45 | 55.45B | ||
| ARGX | ARGENX SE - ADR | 61.95 | 51.15B | ||
| INSM | INSMED INC | N/A | 38.64B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5 | 34.00B | ||
| NTRA | NATERA INC | N/A | 26.94B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.12B | ||
| BIIB | BIOGEN INC | 8.93 | 21.93B |
Related stock screener links
About ONCR
Company Profile
Oncorus, Inc. engages in the research and development of a viral immunotherapy platform. The company is headquartered in Andover, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2020-10-02. The Company’s two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The firm intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The firm is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The firm designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.
Company Info
ONCORUS INC
4 Corporate Drive
Andover MASSACHUSETTS 02139 US
CEO: Theodore (Ted) Ashburn
Employees: 64
Phone: 18573206400.0
ONCORUS INC / ONCR FAQ
What does ONCR do?
Oncorus, Inc. engages in the research and development of a viral immunotherapy platform. The company is headquartered in Andover, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2020-10-02. The Company’s two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The firm intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The firm is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The firm designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.
What is the current price of ONCR stock?
The current stock price of ONCR is 0.1206 USD. The price decreased by -8.5% in the last trading session.
What is the dividend status of ONCORUS INC?
ONCR does not pay a dividend.
What is the ChartMill technical and fundamental rating of ONCR stock?
ONCR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for ONCR stock?
7 analysts have analysed ONCR and the average price target is 5.1 USD. This implies a price increase of 4128.86% is expected in the next year compared to the current price of 0.1206.
How is the valuation of ONCORUS INC (ONCR) based on its PE ratio?
ONCORUS INC (ONCR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.49).
How many employees does ONCORUS INC have?
ONCORUS INC (ONCR) currently has 64 employees.
ONCR Technical Analysis
ONCR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONCR. ONCR has a bad profitability rating. Also its financial health evaluation is rather negative.
ONCR Financial Highlights
Over the last trailing twelve months ONCR reported a non-GAAP Earnings per Share(EPS) of -3.49. The EPS decreased by -28.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ONCR Forecast & Estimates
7 analysts have analysed ONCR and the average price target is 5.1 USD. This implies a price increase of 4128.86% is expected in the next year compared to the current price of 0.1206.